Loading..

Xencor, Inc. (XNCR) Report Analysis

Corporate Events

Negative

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russel...

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive Index

Negative

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russel...

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 3000 Growth Index

Negative

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russel...

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth Index

Negative

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russel...

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell Small Cap Comp Growth Index

Negative

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russel...

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 3000E Growth Index

Negative

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russel...

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2500 Growth Index

Positive

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 20...

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 2000 Value Index

Positive

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 30...

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 3000 Value Index

Positive

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 25...

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 2500 Value Index

Positive

Xencor, Inc.(NasdaqGM:XNCR) added to Russell Sm...

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) added to Russell Small Cap Comp Value Index

Positive

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 30...

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 3000E Value Index

Positive

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 20...

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 2000 Value-Defensive Index

Positive

Xencor, Inc. Reports Initial Dose-Escalation Da...

2022-05-26 21:01:00

Xencor, Inc. reported initial dose-escalation data from the Phase 1 study evaluating XmAb®104, a PD-1 x ICOS bispecific antibody, in patients ...

Neutral

Xencor, Inc. to Report Q1, 2022 Results on May 05, 2022

2022-04-28 20:01:00

Xencor, Inc. announced that they will report Q1, 2022 results After-Market on May 05, 2022

Neutral

Xencor, Inc., Q1 2022 Earnings Call, May 05, 2022

2022-04-28 20:01:00

Xencor, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

Xencor, Inc., Annual General Meeting, Jun 23, 2022

2022-04-27 20:06:00

Xencor, Inc., Annual General Meeting, Jun 23, 2022, at 13:30 Pacific Standard Time. Location: 111 West Lemon Avenue Monrovia California United...

Neutral

Xencor, Inc. Presents at PEGS Boston Conference...

2022-04-23 07:37:00

Xencor, Inc. Presents at PEGS Boston Conference 2022, May-03-2022 02:20 PM. Venue: Boston, Massachusetts, United States. Speakers: John R. Des...

Neutral

Xencor, Inc. Presents at 4th Annual Guggenheim ...

2022-02-02 21:01:00

Xencor, Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 02:00 PM.

Neutral

Guggenheim Securities, LLC, 4th Annual Guggenhe...

2022-01-24 11:50:00

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022.

Neutral

Cambridge Innovation Institute, LLC, PEGS Bosto...

2022-01-13 18:45:00

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022. Venue: Boston, Massachusetts, United States.

Positive

Xencor Presents Data from Phase 1 Study of Plam...

2021-12-12 12:00:00

Xencor, Inc. announced updated data from its Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with B...

Neutral

Xencor, Inc. Presents at Piper Sandler 33rd Ann...

2021-11-22 15:06:00

Xencor, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Positive

Zenas BioPharma Limited acquired Exclusive worl...

2021-11-21 00:00:00

Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR) on November 21, 2021. The rights a...

Neutral

Xencor, Inc. Presents at Piper Sandler 33rd Ann...

2021-11-19 21:01:00

Xencor, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM.

Neutral

Xencor, Inc. Presents at 4th Annual Evercore IS...

2021-11-19 21:01:00

Xencor, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 01:00 PM.

Positive

Xencor, Inc. announced that it has received $25...

2021-11-19 00:00:00

On November 19, 2021, Xencor, Inc. closed the transaction. The company received $25,000,000 pursuant to regulation D from Johnson & Johnson I...

Positive

Xencor Presents Updated Data from the Phase 1 S...

2021-11-12 12:00:00

Xencor, Inc. reported data from its Phase 1 study evaluating vudalimab (XmAb®717), a PD-1 x CTLA-4 bispecific antibody, in patients with advan...

Positive

Xencor, Inc. Presents Data from Multiple Precli...

2021-11-12 12:00:00

Xencor, Inc. announced the presentation of new data from multiple preclinical XmAb® bispecific antibody programs and its preclinical IL-12-Fc ...

Positive

Xencor, Inc. Announces Encouraging Preliminary ...

2021-11-08 21:02:00

Xencor, Inc. announced that XmAb306 is a potency-reduced IL15/IL15Ra-Fc fusion protein that incorporates Xtend extended half-life technology, ...

Positive

Xencor Presents Clinical Data from the Phase 1 ...

2021-11-03 13:00:00

Xencor, Inc. announced updated clinical data from a Phase 1 study of tidutamab, an SSTR2 x CD3 bispecific antibody, in patients with neuroendo...

Neutral

Xencor, Inc. Presents at 12th Annual Jefferies ...

2021-11-02 20:01:00

Xencor, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.

Neutral

Xencor, Inc. to Report Q3, 2021 Results on Nov 08, 2021

2021-11-01 20:01:00

Xencor, Inc. announced that they will report Q3, 2021 results After-Market on Nov 08, 2021

Neutral

Xencor, Inc., Q3 2021 Earnings Call, Nov 08, 2021

2021-11-01 20:01:00

Xencor, Inc., Q3 2021 Earnings Call, Nov 08, 2021

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Neutral

Piper Sandler Companies, Piper Sandler 33rd Ann...

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Neutral

Xencor, Inc. Presents at Antibody Engineering &...

2021-10-06 12:38:00

Xencor, Inc. Presents at Antibody Engineering & Therapeutics US, Dec-12-2021 through Dec-17-2021. Venue: Marriott Marquis San Diego, San Diego...

Neutral

Xencor, Inc. - Special Call

2021-10-04 11:00:00

To discuss Xencor, Inc.'s Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Comb...

Positive

Xencor, Inc. Announces an Exclusive Collaborati...

2021-10-04 11:00:00

Xencor, Inc. announced an exclusive collaboration and worldwide license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutica...

Positive

Xencor, Inc. announced that it expects to recei...

2021-10-04 00:00:00

Xencor, Inc. announced a private placement of common stock for gross proceeds of $25,000,000 on October 4, 2021. The transaction will include ...

Neutral

Xencor, Inc. Presents at 30th Annual Credit Sui...

2021-10-01 10:34:00

Xencor, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-09-2021 02:40 PM. Venue: Rancho Palos Verdes, California, United...

Neutral

Xencor, Inc. Presents at Cantor Global Healthca...

2021-09-20 20:01:00

Xencor, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 04:00 PM. Venue: New York, United States.

Neutral

INmune Bio, Inc. has closed its Shelf Registrat...

2021-09-17 00:00:00

INmune Bio, Inc. has closed its Shelf Registration dated September 07, 2021 in the amount of $5.088647 million. Security Name: Common Stock...

Neutral

INmune Bio, Inc. has filed a Shelf Registration...

2021-09-07 00:00:00

INmune Bio, Inc. has filed a Shelf Registration in the amount of $5.088647 million. Security Name: Common Stock Securities Offered: 192,533

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Xencor, Inc. Presents at 12th Annual Wedbush Pa...

2021-08-02 20:01:00

Xencor, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-10-2021 01:10 PM.

Neutral

Xencor, Inc. Presents at BTIG Virtual Biotechno...

2021-08-02 20:01:00

Xencor, Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 03:30 PM. Speakers: Bassil I. Dahiyat, Co-Founder, CEO, President ...

Neutral

Xencor, Inc. Presents at Canaccord Genuity 41st...

2021-08-02 20:01:00

Xencor, Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-11-2021 04:30 PM. Speakers: Bassil I. Dahiyat, Co-Founder, CEO, ...

Neutral

Sanford C. Bernstein & Co., LLC, Bernstein CD28...

2021-08-02 20:01:00

Sanford C. Bernstein & Co., LLC, Bernstein CD28 Day 2021, Aug 09, 2021.

Neutral

Piper Sandler Companies, Piper Sandler Virtual ...

2021-08-02 20:01:00

Piper Sandler Companies, Piper Sandler Virtual West Coast Bus Tour, Aug 12, 2021.

Neutral

Xencor, Inc. Presents at Bernstein CD28 Day 202...

2021-08-02 20:01:00

Xencor, Inc. Presents at Bernstein CD28 Day 2021, Aug-09-2021 01:00 PM.

Neutral

Xencor, Inc. Presents at Piper Sandler Virtual ...

2021-08-02 20:01:00

Xencor, Inc. Presents at Piper Sandler Virtual West Coast Bus Tour, Aug-12-2021 04:00 PM.

Neutral

Xencor, Inc., Q2 2021 Earnings Call, Aug 04, 2021

2021-07-28 20:01:00

Xencor, Inc., Q2 2021 Earnings Call, Aug 04, 2021

Neutral

Xencor, Inc. to Report Q2, 2021 Results on Aug 04, 2021

2021-07-28 20:01:00

Xencor, Inc. announced that they will report Q2, 2021 results After-Market on Aug 04, 2021

Neutral

BTIG, LLC, BTIG Virtual Biotechnology Conferenc...

2021-07-01 10:09:00

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.

Neutral

Wedbush Securities Inc., 12th Annual Wedbush Pa...

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.

Negative

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive Index

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive Index

Negative

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 3000 Growth Index

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 3000 Growth Index

Negative

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth Index

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth Index

Negative

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell Small Cap Comp Growth Index

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell Small Cap Comp Growth Index

Negative

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 3000E Growth Index

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 3000E Growth Index

Negative

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2500 Growth Index

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2500 Growth Index

Positive

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 2000 Value Index

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 2000 Value Index

Positive

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 3000 Value Index

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 3000 Value Index

Positive

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 2500 Value Index

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 2500 Value Index

Positive

Xencor, Inc.(NasdaqGM:XNCR) added to Russell Small Cap Comp Value Index

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) added to Russell Small Cap Comp Value Index

Positive

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 3000E Value Index

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 3000E Value Index

Positive

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 2000 Value-Defensive Index

2022-06-24 00:00:00

Xencor, Inc.(NasdaqGM:XNCR) added to Russell 2000 Value-Defensive Index

Positive

Xencor, Inc. Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

2022-05-26 21:01:00

Xencor, Inc. reported initial dose-escalation data from the Phase 1 study evaluating XmAb®104, a PD-1 x ICOS bispecific antibody, in patients with advanced solid tumors (DUET-3). These results will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), during the poster session “Developmental Therapeutics—Immunotherapy” on Sunday, June 5, 2022, from 8:00 a.m. to 11 a.m. CDT in Hall A at McCormick Place in Chicago. DUET-3 is an ongoing Phase 1 study of XmAb104 to assess the candidate’s safety and tolerability profile in patients with advanced solid tumors and to determine the maximum tolerated dose (MTD). The expansion portion of the study is currently enrolling patients with colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), non-squamous non-small cell lung cancer (NSCLC), sarcoma, melanoma and clear-cell renal cell carcinoma (RCC) and is randomizing patients 1:1 to receive 10 mg/kg intravenous XmAb104 every two weeks as monotherapy or in combination with ipilimumab.At the data cut off on April 15, 2022, 62 patients had been treated in nine dose-escalation cohorts escalating from 0.002 to 15 mg/kg of XmAb104 administered every other week in four-week cycles. Patients were a median age of 63 years and had a median of three prior systemic therapies. 62.9% of patients had received at least one prior checkpoint therapy, and 91.9% of patients had Stage IV disease. Patients presented with the following primary tumor types: CRC (n=14), pancreatic adenocarcinoma (n=8), soft tissue sarcoma (n=8), melanoma (n=6), HNSCC (n=5), RCC (n=4), endometrial cancer (n=2), NSCLC (n=2) and other solid tumor types (n=8). Of the patients with CRC, eight were microsatellite stable (MSS), three were microsatellite instable (MSI) and three were not defined. Most patients had tumors generally not considered to be sensitive to checkpoint inhibition. Safety and Tolerability: Safety was evaluated in all 62 patients. XmAb104 was well tolerated through the highest tested dose cohort, and treatment-related adverse events (TRAE) were mostly mild. The most common TRAEs (>5 patients) were decreased appetite (9.7%), diarrhea (9.7%), fatigue (9.7%) and maculopapular rash (8.1%). Immune-related adverse events were reported for a limited number of patients, were predominantly Grade 1 or 2, and showed no relationship to dose level. Two patients (3.2%) experienced serious TRAEs, including a Grade 3 hyperbilirubinemia and a Grade 4 asymptomatic lipase increase; both events resolved with prednisone. Four patients (6.5%) discontinued from the study due to an adverse event. No dose-limiting toxicities were observed, and the MTD was not reached. The recommended dose for continued study, based on feasibility of administration at higher dose levels and a review of safety data with investigators, was determined to be 10 mg/kg. Clinical Activity Highlights: The efficacy analysis included 51 evaluable patients who received any amount of XmAb104 and had at least one post-baseline assessment by RECIST 1.1. At the data cut off, two confirmed partial responses (PR), one unconfirmed PR, and stable disease have been observed: A patient with undifferentiated pleomorphic sarcoma, who was immunotherapy naïve, presented with two target lesions in the lung and a subpleural lingular nodule. The patient was enrolled into the 0.2 mg/kg cohort and dose escalated to 0.6 mg/kg. The nodule completely resolved, and a single non-target lesion remained in the lung. The confirmed partial response continued at the time of the data cut (28 months). A patient with clear cell RCC, who had previously received treatment with pembrolizumab/axitinib, presented with two target lesions in the ribs, one target lesion in a lymph node, and a non-target lesion in bone. The patient was treated at the 10 mg/kg dose. A partial response was observed at the end of Cycle 2, and the patient remained in response at the time of the data cut (8 months). A patient with HNSCC, who had recently received treatment with pembrolizumab, was enrolled into the 1.8 mg/kg dose cohort. Prior therapies also included neo-adjuvant nivolumab, cisplatin, nivolumab and a GAL-3 inhibitor, and the patient experienced disease progression on all prior therapies. Two target lesions in the lung were identified, and the patient experienced a partial response at the end of Cycle 2. Two patients with CRC have experienced durable stable disease for over 20 months, both ongoing at the time of data cut. A patient with microsatellite instability high (MSI-H)-CRC was treated at an initial dose of 1.8 mg/kg and dose escalated to 10 mg/kg. Laboratory results indicated a decrease in the tumor marker CEA over time. A second patient, with MSI-H CRC, was treated at the 10 mg/kg dose, and at the time of the data cut, continued to experience stable disease in Cycle 22. Data from assessments of pharmacokinetics (PK) and pharmacodynamics (PD) will not be shown in the poster presentation. The PK analysis indicated a linear and dose-proportional profile. Biomarker analyses indicated complete receptor saturation on peripheral T cells beginning at the 0.6 mg/kg dose level.

Neutral

Xencor, Inc. to Report Q1, 2022 Results on May 05, 2022

2022-04-28 20:01:00

Xencor, Inc. announced that they will report Q1, 2022 results After-Market on May 05, 2022

Neutral

Xencor, Inc., Q1 2022 Earnings Call, May 05, 2022

2022-04-28 20:01:00

Xencor, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

Xencor, Inc., Annual General Meeting, Jun 23, 2022

2022-04-27 20:06:00

Xencor, Inc., Annual General Meeting, Jun 23, 2022, at 13:30 Pacific Standard Time. Location: 111 West Lemon Avenue Monrovia California United States Agenda: To elect the eight nominees to the Board of Directors named in the accompanying proxy statement to serve until the next annual meeting and until successors are duly elected and qualified; to ratify the selection by the Audit Committee of the Board of Directors of RSM US LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022; to hold a non-binding advisory vote on the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement; and to conduct any other business properly brought before the meeting or any adjournments or postponements thereof.

Neutral

Xencor, Inc. Presents at PEGS Boston Conference 2022, May-03-2022 02:20 PM

2022-04-23 07:37:00

Xencor, Inc. Presents at PEGS Boston Conference 2022, May-03-2022 02:20 PM. Venue: Boston, Massachusetts, United States. Speakers: John R. Desjarlais, Senior VP of Research & Chief Scientific Officer.

Neutral

Xencor, Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 02:00 PM

2022-02-02 21:01:00

Xencor, Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 02:00 PM.

Neutral

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022

2022-01-24 11:50:00

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022.

Neutral

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022

2022-01-13 18:45:00

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022. Venue: Boston, Massachusetts, United States.

Positive

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

2021-12-12 12:00:00

Xencor, Inc. announced updated data from its Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with B-cell non-Hodgkin lymphomas. Plamotamab is generally well tolerated and demonstrates encouraging clinical activity in heavily pretreated patients at the company recommended intravenous Phase 2 dose of 50 mg flat dosing every two weeks following step-up dosing. Additionally, the company pharmacokinetic modeling supports subcutaneous administration, which the company plan to incorporate next year into the company ongoing Phase 1 monotherapy study. To that end, early next year the company will initiate the first combination study, with tafasitamab and lenalidomide, in patients with relapsed or refractory diffuse large B cell lymphoma. Additionally, the company new worldwide collaboration with Janssen for advancing plamotamab development expands the company strategy to develop multiple highly active chemotherapy-free regimens across B-cell cancers, importantly with tumor-selective, co-stimulatory CD28 bispecific antibodies. The Phase 1 study of plamotamab was originally designed in two parts: Part A to establish an initial priming dose with fixed, weight-based dosing regimens and Part B to escalate dosing on administrations after the priming dose (doses between 80 and 360 mcg/kg). A third part, Part C, was added to establish a step-up dosing regimen with higher, flat and less frequent dosing. The Part C schedule, an intravenous, 50 mg flat dose every two weeks after step-up dosing during the first two cycles of treatment, was generally well tolerated and was determined to be the recommended Phase 2 dose.

Neutral

Xencor, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021

2021-11-22 15:06:00

Xencor, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Positive

Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR).

2021-11-21 00:00:00

Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR) on November 21, 2021. The rights are to develop, manufacture and commercialize the investigational antibody obexelimab. Under the terms of the new agreement, Zenas will issue to Xencor a warrant giving Xencor the right to acquire additional Zenas equity, such that Xencor’s total equity in Zenas would be 15% of its fully diluted capitalization following the closing of Zenas’ next round of equity financing, subject to certain requirements. Xencor is also eligible to receive up to $480 million based on the achievement of certain clinical development, regulatory and commercialization milestones and is eligible to receive tiered, mid-single digit to mid-teen percent royalties upon commercialization of obexelimab, dependent on geography. Zenas BioPharma Limited completed the acquisition of Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR).

Neutral

Xencor, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM

2021-11-19 21:01:00

Xencor, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM.

Neutral

Xencor, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 01:00 PM

2021-11-19 21:01:00

Xencor, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 01:00 PM.

Positive

Xencor, Inc. announced that it has received $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

2021-11-19 00:00:00

On November 19, 2021, Xencor, Inc. closed the transaction. The company received $25,000,000 pursuant to regulation D from Johnson & Johnson Innovation - JJDC, Inc.

Positive

Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting

2021-11-12 12:00:00

Xencor, Inc. reported data from its Phase 1 study evaluating vudalimab (XmAb®717), a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors (DUET-2). The updated results, predominantly from the study’s expansion cohorts, are presented in a poster titled, “Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors” at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). At the data cut off, 110 patients had been treated at the 10 mg/kg recommended dose level in dose-escalation (n=7) and in five dose expansion cohorts: melanoma (n=20), renal cell carcinoma (RCC, n=21), non-small cell lung cancer (NSCLC, n=20), castration-resistant prostate cancer (CRPC, n=21) and other cancers without approved checkpoint therapies (n=21). 10 mg/kg was identified as the recommended dose for the multi-cohort, parallel-group expansion phase, based on an observation of consistent proliferation of both CD8+ and CD4+ T cells, indicative of dual checkpoint blockade, and a complete response (CR) in one patient with melanoma. The safety analysis includes all 110 patients, who were a median of 65 years old and were heavily pretreated, having a median of four prior systemic therapies. 65% of patients had received at least one prior checkpoint therapy, and 25% had received at least two prior checkpoint therapies. Vudalimab was generally well-tolerated, and the most common treatment-related adverse events were immune-related adverse events (irAEs). The most common irAEs of any grade were rash (45.5%), pruritus (30.9%), transaminase increases (23.6%), diarrhea (11.8%), hypothyroidism (9.1%), infusion related reaction (8.2%) and myalgia (8.2%). As previously reported, immune-mediated pancreatitis (Grade 5) was reported for one patient with RCC, whose cancer had already metastasized to the pancreas at baseline and progressed on study, and Grade 5 myocarditis and respiratory failure were reported for a patient with NSCLC who had a history of significant cardiac events, including atrial fibrillation and the insertion of a dual-chamber pacemaker. The efficacy analysis included 78 evaluable patients receiving any amount of vudalimab, who had been followed for at least two cycles prior to data cut. A complete response was observed in a patient with BRCA1+ high-grade serous ovarian cancer, who had received multiple prior treatments, including olaparib and nivolumab in the metastatic setting. The patient had a partial response after Cycle 4, and by Cycle 18 of treatment all lesions had resolved except a lesion in the abdominal wall, which later showed no cancer cells upon biopsy. A confirmed complete response was observed in a patient with melanoma during dose-escalation at the 10 mg/kg dose level, as previously reported. Partial responses were observed in patients with melanoma (n=2), RCC (n=3), NSCLC (n=2) and CRPC (n=2). The objective response rate across cohorts was 14.1% (11/78). All responses in patients with melanoma and CRPC and two responses in patients with RCC were confirmed. All responders, except those with CRPC, had received prior checkpoint inhibitor therapy. Of the 12 efficacy-evaluable patients with CRPC, four had measurable disease and follow-up RECIST assessments, including the two CRPC responders. Six additional patients with CRPC, but without measurable disease, experienced a best overall response of non-CR/non-PD, as stable disease cannot be determined without measurable disease. The two CRPC responders had visceral and nodal metastases, had response durations of 41.3 and 27.0 weeks, were without progression on bone scans and had confirmed prostate-specific antigen (PSA) reductions of more than 50% from baseline. Among twelve patients with baseline and follow-up PSA assessments, including the two responders, 33% (4/12) had PSA reductions greater than 50%.

Positive

Xencor, Inc. Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, At the SITC Annual Meeting

2021-11-12 12:00:00

Xencor, Inc. announced the presentation of new data from multiple preclinical XmAb® bispecific antibody programs and its preclinical IL-12-Fc cytokine program, XmAb662, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Abstract 707, “IL12 Fc-fusions engineered for reduced potency and extended half-life exhibit strong anti-tumor activity and improved therapeutic index compared to wild-type IL12 agents”: IL-12 is a potent pro-inflammatory cytokine that promotes high levels of interferon gamma secretion from T-cells and NK cells, increasing their cytotoxicity and the immunogenicity of the tumor microenvironment by making tumor antigens more visible to the immune system. Prior clinical studies have demonstrated IL-12 has significant anti-tumor activity; however, its toxicity has limited its potential. Xencor’s IL-12 program follows the same potency reduction design strategy as the Company’s IL15-Fc fusions in oncology, where reduced potency led to improved pharmacokinetics, pharmacodynamics and safety in preclinical studies. In addition, preliminary clinical data from Xencor’s IL15-Fc program, XmAb306, showed generally good tolerability and robust and sustained immune cell expansion. IL12-Fc fusions were engineered with reduced potency in order to improve potential tolerability, slow receptor-mediated clearance and prolong half-life in vivo, compared to native IL-12. These potency-reduced IL12-Fc fusions demonstrated significant anti-tumor activity in vivo, concurrent with activation and proliferation of CD8+ T cells and with interferon gamma production. The addition of Xencor’s half-life extending Xtend™ Fc mutations further improved exposure of the molecules over time. In non-human primates, the engineered cytokines had an improved pharmacokinetic profile and therapeutic window compared to a native cytokine-Fc fusion, with superior exposure, a more gradual dose response and similar levels of cytokine production in serum. XmAb662 was selected for further development and demonstrated significant anti-tumor activity in vivo, concurrent with increases in NK cells, T cells, serum IP10 and serum interferon gamma, which were further enhanced when combined with an anti-PD-1 antibody. The Company anticipates submitting an IND application for XmAb662 in 2022. Abstract 698, “PDL1-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors”: T cells in the tumor microenvironment require both T cell receptor (TCR) and co-stimulatory receptor engagement to achieve full activation. CD28 is a key immune co-stimulatory receptor on T cells; however, the ligands that activate T cells through CD28 are usually not expressed on tumor cells. Targeted CD28 bispecific antibodies, a new class of T cell engager, may provide conditional co-stimulation of T cells, for example, to T cells recognizing neoantigens or in concert with CD3 T-cell engaging bispecific antibodies. Xencor engineered PD-L1 x CD28 bispecific antibodies to provide conditional co-stimulation of T cells, activating them when bound to PD-L1+ cells. PD-L1, which is expressed on many types of tumors, suppresses anti-tumor responses by the immune system and can inhibit CD28 by engaging PD-1. A PD-L1 x CD28 bispecific antibody, therefore, may promote CD28 co-stimulation and simultaneously block CD28's suppression by PD-1. In vitro, the combination of the PD-L1 x CD28 and a CD3 T cell engager enhanced T cell activation and proliferation compared to the CD3 bispecific alone. PD-L1 x CD28 also enhanced the interaction between T cells and antigen presenting cells and exhibited strong CD28-dependent anti-tumor activity in mice. PD-L1 x CD28 was well tolerated in non-human primates and exhibited favorable pharmacokinetics. Modeling and preclinical data suggest a dosing schedule consistent with typical checkpoint inhibitor regimens. Abstract 872, “PD1 x TGFßR2 and CD5 x TGFßR2 bispecifics selectively block TGFßR2 on target-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors”: TGFß is an inhibitory cytokine, and its production in solid tumors is a significant mechanism used by tumors to avoid recognition by the immune system. While TGFß inhibition is expected to promote an anti-tumor response, systemic blockade of TGFß has also been associated with toxicity. Xencor engineered two XmAb bispecific antibodies, PD-1 x TGFßR2 and CD5 x TGFßR2, to selectively block the suppressive activity of TGFß on specific T-cell populations and to enhance their anti-tumor activity while avoiding the toxicity associated with systemic blockade. PD-1 and CD5 were selected to direct TGFß blockade to activated or all T cells, respectively. In vitro, both bispecific antibodies exhibited highly selective blocking of TGFß activity in PD-1-high and CD5-positive T cell populations. PD-1 x TGFßR2 and CD5 x TGFßR2 were active in vivo and promoted T cell engraftment and anti-tumor response. Anti-tumor activity was significantly enhanced when combined with an anti-PD-1 antibody, compared to either anti-PD-1 or the bispecific antibody alone.

Positive

Xencor, Inc. Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-Reduced Il15-Fc Cytokine, Xmab306

2021-11-08 21:02:00

Xencor, Inc. announced that XmAb306 is a potency-reduced IL15/IL15Ra-Fc fusion protein that incorporates Xtend extended half-life technology, and Xencor is co-developing the program in collaboration with Genentech, a member of the Roche Group. An ongoing Phase 1 dose-escalation study of XmAb306 in patients with advanced solid tumors has enrolled six cohorts in a monotherapy arm and four cohorts in an atezolizumab combination arm, and further dose escalation in both study arms is continuing. XmAb306 has been generally well tolerated as both a monotherapy and in combination with atezolizumab. No dose-limiting toxicities or treatment-related serious adverse events have been observed to date. Assessments of pharmacokinetics indicate that XmAb306 has a multi-day circulating half-life, which is consistent with its reduced-potency design and data generated in preclinical studies. Unconfirmed responses, as evaluated by RECIST criteria, have been observed in multiple tumor types, including in a patient treated with XmAb306 monotherapy. In recently dosed cohorts, the study has reached dose levels that promote T cell activity, and evidence of peripheral effector T cell proliferation has been observed. Consistent and robust dose-dependent natural killer cell expansion and NK cell accumulation upon repeat dosing has been observed for multiple NK cell subsets, including mature NK cells. Significant NK cell expansion and accumulation was observed beginning in lower dose cohorts, and at higher dosing cohorts NK cell expansion has reached 40- to 100-fold higher levels than baseline and has been sustained for weeks throughout dosing. Additional studies of XmAb306 in combination with other agents are being planned. Under its agreement with Genentech, Xencor shares in 45% of worldwide development and commercialization costs for XmAb306 and will receive a share of net profits or net losses from product sales at the same percentage rate.

Positive

Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium

2021-11-03 13:00:00

Xencor, Inc. announced updated clinical data from a Phase 1 study of tidutamab, an SSTR2 x CD3 bispecific antibody, in patients with neuroendocrine tumors (NETs). The data will be presented during the North American Neuroendocrine Tumor Society’s 2021 Multidisciplinary NET Medical Virtual Symposium (NANETS). The primary objectives of the Phase 1 study were to determine the safety and tolerability profile of tidutamab in patients with advanced, well-differentiated NETs of pancreatic, gastrointestinal, lung and undetermined origin, and to identify the maximum tolerated dose and/or recommended dosing regimen for continued study, which was determined to be a 0.3 mcg/kg priming dose followed by 1.0 mcg/kg on subsequent dosing days. At data cut-off in August 2021, 41 patients with neuroendocrine tumors, with the initial lesion location in the pancreas (46%), intestine (22%), lung (20%), and other GEP-NET or unknown (12%), received doses of tidutamab ranging from 0.1 to 2.0 mcg/kg. Dosing in the study included a lower priming dose, followed by a higher repeated dose on subsequent dosing days. The 20 patients in the expansion cohort received the recommended dosing regimen. Patients had a median age of 64 years and a median of four prior lines of systemic therapies. Fifty percent of patients received prior peptide receptor radionuclide therapy. Tidutamab was generally well tolerated at the 0.3/1.0 mcg/kg dose identified for the expansion portion of the study. All 41 patients treated were included in the safety analysis. The most common treatment-related Grade 3 or Grade 4 adverse events across all doses were lymphopenia (29%), gamma-glutamyl transferase increases (20%), transaminase increases (20%) and vomiting (17%). In addition, Grade 3 esophageal dysmotility was observed in 7% of patients. CRS of any grade was observed in 41% of patients. The majority of CRS was limited to Grade 1 and Grade 2 and to the first two doses. Grade 3 CRS was observed in two patients (5%) upon the first dose. All patients experiencing CRS fully recovered. Analysis of peripheral blood biomarkers indicated that tidutamab induced acute and sustained T-cell activation at the recommended dose for expansion. CD8-positive effector T cells showed a dose-dependent increase in proliferation (Ki67) and activation (PD-1) markers that began within 48 hours of the first dose and persisted at least seven weeks, as measured at cycle 2, day 22. The best overall response was stable disease, with a disease control rate of 27%. Higher tumor PD-L1 expression was associated with a shorter time on study, and the patients with prolonged stable disease were most likely to have low or absent PD-L1 expression, suggesting a potential beneficial effect from the combination of tidutamab with PD-L1 inhibitors.

Neutral

Xencor, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM

2021-11-02 20:01:00

Xencor, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.

Neutral

Xencor, Inc. to Report Q3, 2021 Results on Nov 08, 2021

2021-11-01 20:01:00

Xencor, Inc. announced that they will report Q3, 2021 results After-Market on Nov 08, 2021

Neutral

Xencor, Inc., Q3 2021 Earnings Call, Nov 08, 2021

2021-11-01 20:01:00

Xencor, Inc., Q3 2021 Earnings Call, Nov 08, 2021

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Neutral

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Neutral

Xencor, Inc. Presents at Antibody Engineering & Therapeutics US, Dec-12-2021 through Dec-17-2021

2021-10-06 12:38:00

Xencor, Inc. Presents at Antibody Engineering & Therapeutics US, Dec-12-2021 through Dec-17-2021. Venue: Marriott Marquis San Diego, San Diego, California, United States. Presentation Date & Speakers: Dec-15-2021, Gregory Moore, Director, Protein Engineering, James A. Ernst, Senior Director, Head of Development Sciences.

Neutral

Xencor, Inc. - Special Call

2021-10-04 11:00:00

To discuss Xencor, Inc.'s Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies

Positive

Xencor, Inc. Announces an Exclusive Collaboration and Worldwide License Agreement with Janssen Biotech, Inc

2021-10-04 11:00:00

Xencor, Inc. announced an exclusive collaboration and worldwide license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize plamotamab and novel XmAb B-cell targeting bispecific antibodies that are designed to conditionally activate T cells through the CD28 co-stimulatory receptor. Plamotamab is a CD20 x CD3 XmAb bispecific antibody and is currently completing a Phase 1 dose-escalation study in patients with CD20-expressing hematologic malignancies. Under the terms of the agreement, Janssen will receive worldwide exclusive development and commercialization rights to plamotamab, whether as a monotherapy or in combination regimens. Xencor will collaborate with Janssen on further clinical development of plamotamab with Janssen paying 80% and Xencor paying 20% of costs, including those for a subcutaneous formulation anticipated to enter clinical trials in 2022. In parallel, Xencor will continue, at its own expense, a previously announced clinical collaboration to evaluate the combination of plamotamab, tafasitamab and lenalidomide in patients with B-cell lymphoma, including a Phase 2 trial in relapsed or refractory diffuse large B-cell lymphoma anticipated to start in late 2021 or early 2022. Further, Xencor will apply its XmAb bispecific Fc technology to create and characterize XmAb CD28 bispecific antibody candidates against B-cell targets during a two-year joint research collaboration, and Janssen will have an exclusive worldwide license to develop selected molecules in combination with plamotamab and other agents, such as CD3 bispecific antibodies. The agreement is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and closing is expected to occur in the fourth quarter of 2021.

Positive

Xencor, Inc. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

2021-10-04 00:00:00

Xencor, Inc. announced a private placement of common stock for gross proceeds of $25,000,000 on October 4, 2021. The transaction will include participation from Johnson & Johnson Innovation - JJDC, Inc. The transaction is expected to close in the fourth quarter of 2021 and is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act,

Neutral

Xencor, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-09-2021 02:40 PM

2021-10-01 10:34:00

Xencor, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-09-2021 02:40 PM. Venue: Rancho Palos Verdes, California, United States. Speakers: Bassil I. Dahiyat, Co-Founder, CEO, President & Director.

Neutral

Xencor, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 04:00 PM

2021-09-20 20:01:00

Xencor, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 04:00 PM. Venue: New York, United States.

Neutral

INmune Bio, Inc. has closed its Shelf Registration dated September 07, 2021 in the amount of $5.088647 million.

2021-09-17 00:00:00

INmune Bio, Inc. has closed its Shelf Registration dated September 07, 2021 in the amount of $5.088647 million. Security Name: Common Stock Securities Offered: 192,533

Neutral

INmune Bio, Inc. has filed a Shelf Registration in the amount of $5.088647 million.

2021-09-07 00:00:00

INmune Bio, Inc. has filed a Shelf Registration in the amount of $5.088647 million. Security Name: Common Stock Securities Offered: 192,533

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Xencor, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-10-2021 01:10 PM

2021-08-02 20:01:00

Xencor, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-10-2021 01:10 PM.

Neutral

Xencor, Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 03:30 PM

2021-08-02 20:01:00

Xencor, Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 03:30 PM. Speakers: Bassil I. Dahiyat, Co-Founder, CEO, President & Director, Charles Liles, Associate Director and Head of Corporate Communications & Investor Relations.

Neutral

Xencor, Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-11-2021 04:30 PM

2021-08-02 20:01:00

Xencor, Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-11-2021 04:30 PM. Speakers: Bassil I. Dahiyat, Co-Founder, CEO, President & Director, Charles Liles, Associate Director and Head of Corporate Communications & Investor Relations.

Neutral

Sanford C. Bernstein & Co., LLC, Bernstein CD28 Day 2021, Aug 09, 2021

2021-08-02 20:01:00

Sanford C. Bernstein & Co., LLC, Bernstein CD28 Day 2021, Aug 09, 2021.

Neutral

Piper Sandler Companies, Piper Sandler Virtual West Coast Bus Tour, Aug 12, 2021

2021-08-02 20:01:00

Piper Sandler Companies, Piper Sandler Virtual West Coast Bus Tour, Aug 12, 2021.

Neutral

Xencor, Inc. Presents at Bernstein CD28 Day 2021, Aug-09-2021 01:00 PM

2021-08-02 20:01:00

Xencor, Inc. Presents at Bernstein CD28 Day 2021, Aug-09-2021 01:00 PM.

Neutral

Xencor, Inc. Presents at Piper Sandler Virtual West Coast Bus Tour, Aug-12-2021 04:00 PM

2021-08-02 20:01:00

Xencor, Inc. Presents at Piper Sandler Virtual West Coast Bus Tour, Aug-12-2021 04:00 PM.

Neutral

Xencor, Inc., Q2 2021 Earnings Call, Aug 04, 2021

2021-07-28 20:01:00

Xencor, Inc., Q2 2021 Earnings Call, Aug 04, 2021

Neutral

Xencor, Inc. to Report Q2, 2021 Results on Aug 04, 2021

2021-07-28 20:01:00

Xencor, Inc. announced that they will report Q2, 2021 results After-Market on Aug 04, 2021

Neutral

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021

2021-07-01 10:09:00

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.

Neutral

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.

Fundamental Summary

According to their recent financial report, which was published on 2022-05-05, Xencor had several impressive financial metrics that should make them more attractive than their peers going forward. Their growth and income factors indicate a well-executed and balanced strategy, which is generating exciting growth. These results lead us to believe that there should be significant upside potential for the stock. As such, Xencor received an overall score of 82 and a BUY recommendation.

Xencor reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net income was USD 23.59 million compared to net loss of USD 2.49 million a year ago. Basic earnings per share from continuing operations was USD 0.4 compared to basic loss per share from continuing operations of USD 0.04 a year ago. Diluted earnings per share from continuing operations was USD 0.39 compared to diluted loss per share from continuing operations of USD 0.04 a year ago.

Business Description

Xencor, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. In addition, it is developing VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. Further, the company is developing AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer’s disease, mild cognitive impairment, and depression. Xencor was incorporated in 1997 and is headquartered in Monrovia, California.

Sector Overview

Xencor is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Xencor's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 857.9 2.4% 78
Liabilities 94.9 -9.4% 53
Price to Book 1.7 -48.6% 67
Cash & Equivalents 78.3 -45.5% 40
Equity 763.0 4.0% 60
EBITDA 100.3 77.2% 94
Total Revenues 326.6 18.7% 42
Parameter Value Change Score
Return on Equity 16.1 27.6% 52
Net Cashflow -98.7 -391.9% 96
Capital Expenditure -13.4 -1.0% 70
Asset Turnover 0.4 18.0% 95
Free Cashflow 0.0 106.0% 95

* All values are TTM

The below chart reflects Xencor's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Xencor's peer average final assessment score stands on 65.0, Xencor's score is 82.

  •  XNCR
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 0 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 1 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 2 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 3 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 4 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 5 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 6 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 7 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 8 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 9 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 10 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 11 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 12 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 13 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 14 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 15 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 16 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 17 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 18 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 19 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 20 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 22 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 23 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 24 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 26 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 27 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 28 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 30 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 31 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 32 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 33 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 34 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 35 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 36 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 37 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 39 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 40 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 41 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 42 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 43 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 44 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 46 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 47 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 48 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 50 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 54 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 55 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 57 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 58 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 59 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 60 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 61 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 62 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 65 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 66 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 69 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 70 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 73 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 74 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 75 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 76 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 77 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 80 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 81 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 82 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 83 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 84 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 85 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 92 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 93 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Xencor's stock is now priced above its 5-day and 50-day, but below its 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in both the short and medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Xencor's stock indicates that it's likely oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 68.

Neutral 68
Close Price 27.06
52W Low 19.74
52W High 43.44
5D MA 26.55
50D MA 23.96
200D MA 31.85
MACD 0.85
RSI 25.97
STOCH 91.27

Balance Sheet Analysis

Xencor appears likely to maintain its strong balance sheet metrics and momentum going forward. The company's assets section could set high expectations for Xencor's future attractiveness, as they went to 857.9, which is a 2.4% change from the last period. This performance is interesting in comparison to its peers and competitors. Consequently, their asset movement received a grade of 78. Also, Xencor's price to book ratio (P/B) was reported as 1.7 and represents -48.6% change from the previous report. The company's book value factor metrics are even more remarkable when compared to their peers. The company's book value factors component, therefore, received a grade of 67. On the other hand, Cash & Equivalents, jumped out as looking rather underwhelming. Xencor's management did a relatively poor job managing cash and cash equivalents, which now sit at 78.3 and represents a -45.5% change from the last reporting period. This performance is significantly less impressive than its peers and competitors. Consequently, their cash and cash equivalents movement received a grade of 40. Therefore, the company's balance sheet earned a grade of 67.

Parameter Value Change Score
Assets 857.9 2.4% 78
Liabilities 94.9 -9.4% 53
Price to Book 1.7 -48.6% 67
Cash & Equivalents 78.3 -45.5% 40
Equity 763.0 4.0% 60
* All values are TTM

The below chart describes Xencor's performance as reflected on its balance sheet with respect to its peers. While Xencor received a balance sheet score of 67, the average of its peers stands on 65.0.

  •  XNCR
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 0 1
CureVac N.V. 2.6B 49 64 75 52 52 57 1 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 2 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 3 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 4 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 5 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 6 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 7 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 8 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 9 1
CareDx, Inc 1.2B 54 67 52 39 51 52 10 1
MannKind Corporation 957.2M 79 59 50 40 64 57 11 1
Merus N.V. 941.6M 59 68 50 83 81 70 12 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 13 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 14 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 15 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 16 1
Affimed N.V. 415.0M 56 66 63 56 47 54 17 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 18 1
AC Immune SA 299.8M 84 64 47 53 75 68 19 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 20 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 22 1
Amgen Inc. 130.1B 72 68 86 53 62 69 23 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 24 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 26 1
BioNTech SE 34.0B 75 69 64 97 73 75 27 1
Seagen Inc. 32.9B 59 68 55 43 66 61 28 1
Biogen Inc. 29.7B 57 72 92 50 76 76 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 30 1
Incyte Corporation 16.8B 71 72 95 82 79 83 31 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 32 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 33 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 34 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 35 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 36 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 37 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 38 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 39 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 40 1
Alkermes plc 5.0B 63 66 46 54 71 62 41 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 42 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 43 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 44 1
Natera, Inc. 3.6B 73 65 43 95 42 54 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 46 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 47 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 48 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 50 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 54 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 55 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 57 1
Vericel Corporation 1.1B 51 65 56 53 61 57 58 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 59 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 60 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 61 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 62 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 63 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 65 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 66 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 69 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 70 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 73 1
Geron Corporation 566.2M 69 72 37 59 62 60 74 1
Immatics N.V. 538.7M 56 70 84 95 73 76 75 1
Agenus Inc. 520.5M 73 62 37 55 60 54 76 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 77 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 80 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 81 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 82 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 83 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 84 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 85 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 92 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 93 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Xencor appears likely to maintain its strong income statement metrics and momentum going forward. Xencor reported impressive EBITDA this period. At filing, EBITDA was reported as 100.3, representing 77.2% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Its EBITDA metrics highlight an impressive overall financial performance, which is expected to continue moving forward. The company's EBITDA movement, therefore, received a grade of 94. Also, Xencor's reported return on equity (ROE) ratio was 16.1, representing a change of 27.6%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Consequently, their return factors received a grade of 52. That said, one metric, Revenue Efficiency, stood out as particularly concerning. Xencor reported discouraging numbers for its revenue efficiency. As of the current filing, they were reported as 326.6 and represented 18.7% change from the previous period. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Its uninspiring revenue efficiency is even more concerning relative to its peers and competitors in the current market. As a result, their revenue efficiency earned a score of 42. Therefore, it received a score of 79.

Parameter Value Change Score
EBITDA 100.3 77.2% 94
Total Revenues 326.6 18.7% 42
Return on Equity 16.1 27.6% 52
* All values are TTM

The below chart describes Xencor's performance as reflected on its income statement with respect to its peers. While Xencor received a income statement score of 79 , the average of its peers stands on 65.0.

  •  XNCR
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 0 1
CureVac N.V. 2.6B 45 83 71 74 1 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 2 1
Abgenix Inc. 2.1B 47 47 47 47 3 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 4 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 5 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 6 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 7 1
Veracyte, Inc. 1.4B 45 63 57 55 8 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 9 1
CareDx, Inc 1.2B 61 44 82 50 10 1
MannKind Corporation 957.2M 95 48 56 61 11 1
Merus N.V. 941.6M 48 60 59 54 12 1
Amarin Corporation plc 734.5M 95 44 82 63 13 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 14 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 15 1
Radius Health, Inc. 499.8M 94 71 68 82 16 1
Affimed N.V. 415.0M 95 49 75 66 17 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 18 1
AC Immune SA 299.8M 83 61 65 70 19 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 20 1
Chimerix, Inc. 178.4M 99 50 62 65 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 22 1
Amgen Inc. 130.1B 74 75 64 78 23 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 24 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 26 1
BioNTech SE 34.0B 41 89 75 79 27 1
Seagen Inc. 32.9B 54 65 70 62 28 1
Biogen Inc. 29.7B 90 57 73 70 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 30 1
Incyte Corporation 16.8B 59 77 60 73 31 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 32 1
United Therapeutics Corporation 10.6B 57 91 54 82 33 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 34 1
Exact Sciences Corporation 7.2B 57 67 54 62 35 1
Exelixis, Inc. 6.7B 54 91 54 81 36 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 37 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 39 1
Ascendis Pharma A/S 5.2B 38 68 46 54 40 1
Alkermes plc 5.0B 69 55 81 62 41 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 42 1
Novavax, Inc. 4.0B 41 89 54 75 43 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 44 1
Natera, Inc. 3.6B 52 51 78 52 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 46 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 47 1
Insmed Incorporated 2.4B 51 58 73 57 48 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 50 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 54 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 55 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 56 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 57 1
Vericel Corporation 1.1B 76 44 82 56 58 1
IVERIC bio, Inc. 1.1B 84 58 79 70 59 1
FibroGen, Inc. 1.0B 48 74 63 67 60 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 61 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 62 1
ImmunoGen, Inc. 946.1M 40 73 71 64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 65 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 66 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 68 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 69 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 70 1
CTI BioPharma Corp. 603.6M 84 50 62 59 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
AnaptysBio, Inc. 586.3M 97 50 77 68 73 1
Geron Corporation 566.2M 89 67 73 78 74 1
Immatics N.V. 538.7M 37 93 53 77 75 1
Agenus Inc. 520.5M 57 83 45 74 76 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 77 1
Vaxart, Inc. 440.0M 99 51 72 68 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
MiMedx Group, Inc. 391.5M 87 43 83 59 80 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 81 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 82 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 83 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 84 1
Zymeworks Inc. 324.7M 58 53 77 56 85 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
Precigen, Inc. 299.1M 57 87 59 79 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
bluebird bio, Inc. 288.7M 99 91 61 96 92 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 93 1
MacroGenics, Inc. 184.6M 95 56 74 71 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Xencor appears likely to maintain its strong cash flow metrics and momentum going forward. Xencor presents exciting net cash flow numbers for its recent financial release, illustrated by a net cash flow of -98.7, which is a change of -391.9% from the last filing. Their net cash flow metrics are especially remarkable relative to their peers. Hence, its net cash flow earned a score of 96. Also, Xencor is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.4, representing a 18.0% change from the previous period. This metric might have a 4.1 percent impact on companies in the same industry and with the same market capitalization. Its asset turnover metrics are especially remarkable relative to their peers. We believe the stock price has room to grow to reflect its intrinsic value accurately. The company's asset turnover movement, therefore, received a grade of 95. On the other hand, Capital Expenditure, jumped out as looking rather underwhelming. Xencor's management was ineffective in materially improving CapEx, which now sits at -13.4 and represents a -1.0% change from the previous report. The company's disappointing CapEx growth is expected to stunt the momentum they hoped for this period. Therefore, their CapEx movement component earned a score of 70. Its cash flow received an overall score of 98.

Parameter Value Change Score
Net Cashflow -98.7 -391.9% 96
Capital Expenditure -13.4 -1.0% 70
Asset Turnover 0.4 18.0% 95
Free Cashflow 0.0 106.0% 95
* All values are TTM

The below chart describes Xencor's performance as reflected on its cash flow with respect to its peers. While Xencor received a cash flow score of 98, the average of its peers stands on 67.0.

  •  XNCR
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 0 1
CureVac N.V. 2.6B 87 80 90 70 90 1 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 2 1
Abgenix Inc. 2.1B 66 53 45 59 58 3 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 4 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 5 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 6 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 7 1
Veracyte, Inc. 1.4B 90 95 46 46 82 8 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 9 1
CareDx, Inc 1.2B 98 84 40 50 86 10 1
MannKind Corporation 957.2M 77 56 43 37 66 11 1
Merus N.V. 941.6M 70 71 74 53 71 12 1
Amarin Corporation plc 734.5M 52 40 74 55 55 13 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 14 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 15 1
Radius Health, Inc. 499.8M 64 40 37 56 57 16 1
Affimed N.V. 415.0M 72 57 95 43 74 17 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 18 1
AC Immune SA 299.8M 66 77 79 63 68 19 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 20 1
Chimerix, Inc. 178.4M 80 84 95 47 83 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 22 1
Amgen Inc. 130.1B 80 74 67 74 81 23 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 24 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 26 1
BioNTech SE 34.0B 73 97 50 52 72 27 1
Seagen Inc. 32.9B 53 53 50 87 58 28 1
Biogen Inc. 29.7B 58 54 90 73 66 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 30 1
Incyte Corporation 16.8B 78 79 92 74 84 31 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 32 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 33 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 34 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 35 1
Exelixis, Inc. 6.7B 79 90 89 83 87 36 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 37 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 38 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 39 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 40 1
Alkermes plc 5.0B 89 95 76 80 92 41 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 42 1
Novavax, Inc. 4.0B 62 38 63 54 60 43 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 44 1
Natera, Inc. 3.6B 52 54 56 84 58 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 46 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 47 1
Insmed Incorporated 2.4B 79 80 61 89 82 48 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 50 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 54 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 55 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 56 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 57 1
Vericel Corporation 1.1B 64 46 59 73 65 58 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 59 1
FibroGen, Inc. 1.0B 86 74 48 87 84 60 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 61 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 62 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 63 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 65 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 66 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 68 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 69 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 70 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 73 1
Geron Corporation 566.2M 78 68 49 81 77 74 1
Immatics N.V. 538.7M 82 95 56 99 86 75 1
Agenus Inc. 520.5M 57 43 52 77 58 76 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 77 1
Vaxart, Inc. 440.0M 72 56 53 38 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 80 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 81 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 82 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 83 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 84 1
Zymeworks Inc. 324.7M 52 65 45 83 57 85 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
Precigen, Inc. 299.1M 82 75 37 85 74 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 92 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 93 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.